FULC
Fulcrum Therapeutics Inc
$
6.850
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
6.925
Open
6.610
VWAP
6.79
Vol
307.46K
Mkt Cap
370.53M
Low
6.540
Amount
2.09M
EV/EBITDA(TTM)
--
Total Shares
62.15M
EV
139.65M
EV/OCF(TTM)
--
P/S(TTM)
--
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company's lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD). It uses technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. In addition to its product candidates, the Company has developed a discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The Company continues to advance its program for the potential treatment of inherited aplastic anemias, such as Diamond-Blackfan anemia (DBA), Shwachman-Diamond syndrome, and Fanconi anemia.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
--
--
-0.294
-36.6%
--
--
-0.296
-4.44%
--
--
-0.300
+7.14%
Estimates Revision
The market is revising No Change the revenue expectations for Fulcrum Therapeutics, Inc. (FULC) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 21.67%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-2.14%
In Past 3 Month
Stock Price
Go Up
+21.67%
In Past 3 Month
8 Analyst Rating
39.56% Upside
Wall Street analysts forecast FULC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FULC is 9.56 USD with a low forecast of 5.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
2 Hold
1 Sell
Moderate Buy
39.56% Upside
Current: 6.850
Low
5.00
Averages
9.56
High
15.00
39.56% Upside
Current: 6.850
Low
5.00
Averages
9.56
High
15.00
Oppenheimer
Oppenheimer
Outperform
maintain
$12 -> $15
2025-07-29
Reason
Oppenheimer
Oppenheimer
Price Target
$12 -> $15
2025-07-29
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Fulcrum Therapeutics to $15 from $12 and keeps an Outperform rating on the shares after the company read out 12-week results from the 12 mg cohort of its sickle cell drug pociredir. Alongside improvements in red cell health and VOC reductions, Oppenheimer thinks these data suggest pociredir may be the first drug since hydroxyurea to address all the consequences of SCD. With nearly half of patients achieving greater than20% total HbF, the firm thinks this is already a drug that will benefit the majority.
H.C. Wainwright
Neutral -> Buy
upgrade
$4 -> $12
2025-07-29
Reason
H.C. Wainwright
Price Target
$4 -> $12
2025-07-29
upgrade
Neutral -> Buy
Reason
H.C. Wainwright upgraded Fulcrum Therapeutics to Buy from Neutral with a price target of $12, up from $4.
H.C. Wainwright
H.C. Wainwright
Neutral -> Buy
upgrade
$4 -> $12
2025-07-29
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$4 -> $12
2025-07-29
upgrade
Neutral -> Buy
Reason
H.C. Wainwright upgraded Fulcrum Therapeutics to Buy from Neutral with a price target of $12, up from $4. The stock in late morning trading is down 5% to $7.40. Data from Fulcrum's PIONEER Phase 1b trial represent a "clinically meaningful inflection" for pociredir in sickle cell disease, the analyst tells investors in a research note. The firm says the increase in fetal hemoglobin and improvements in key hematologic and hemolytic parameters are validation of pociredir's ability to recapitulate the protective biology observed in hereditary persistence of fetal hemoglobin. It believes this morning's update "meaningfully de-risks the program."
Goldman Sachs
Corinne Johnson
initiated
2025-07-10
Reason
Goldman Sachs
Corinne Johnson
Price Target
2025-07-10
initiated
Reason
Goldman Sachs analyst Corinne Johnson started Fulcrum Therapeutics with an Early-Stage Biotech rating.
BofA
Underperform
maintain
$2 -> $6
2025-06-30
Reason
BofA
Price Target
$2 -> $6
2025-06-30
maintain
Underperform
Reason
BofA raised the firm's price target on Fulcrum Therapeutics to $6 from $2 and keeps an Underperform rating on the shares, citing primarily a higher likelihood of success for its lead program in sickle cell disease for the firm's increased target. Based on clinical data presented to-date and key opinion leader feedback on their potential use of pociredir and long-term safety concerns, the firm refreshed its view on the program and adjusted its risk estimates, but BofA believes Fulcrum's upside is capped with the recent upward stock price move, the analyst tells investors.
Piper Sandler
Edward Tenthoff
Overweight
maintain
$6 -> $9
2025-05-29
Reason
Piper Sandler
Edward Tenthoff
Price Target
$6 -> $9
2025-05-29
maintain
Overweight
Reason
Piper Sandler analyst Edward Tenthoff raised the firm's price target on Fulcrum Therapeutics to $9 from $6 ahead of upcoming PIONEER data, while keeping an Overweight rating on the shares. The firm notes Fulcrum expects to report Phase Ib PIONEER data from the 12mg pociredir cohort in early Q3 2025. Prior Phase Ib data showed 12mg pociredir achieved HbF protein increases of up to 10% from baseline to a total HbF level of 25%, which could represent a clinically transformative benefit. Pociredir was well tolerated with no drug-related SAEs or discontinuations due to TEAEs.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Fulcrum Therapeutics Inc (FULC.O) is -5.37, compared to its 5-year average forward P/E of -5.83. For a more detailed relative valuation and DCF analysis to assess Fulcrum Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-5.83
Current PE
-5.37
Overvalued PE
1.68
Undervalued PE
-13.33
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-2.50
Current EV/EBITDA
-1.52
Overvalued EV/EBITDA
0.79
Undervalued EV/EBITDA
-5.79
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
52.20
Current PS
0.00
Overvalued PS
116.25
Undervalued PS
-11.85
Financials
Annual
Quarterly
FY2025Q2
YoY :
-100.00%
0.00
Total Revenue
FY2025Q2
YoY :
-137.56%
-19.72M
Operating Profit
FY2025Q2
YoY :
-131.22%
-17.30M
Net Income after Tax
FY2025Q2
YoY :
-132.18%
-0.28
EPS - Diluted
FY2025Q2
YoY :
-123.57%
-13.89M
Free Cash Flow
FY2025Q2
YoY :
-100.00%
N/A
Gross Profit Margin - %
FY2025Q2
YoY :
-100.00%
N/A
FCF Margin - %
FY2025Q2
YoY :
-100.00%
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
2.5K
USD
1
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
1.4M
Volume
1
Bought
0-3
0
0.0
Volume
Months
3-6
1
1.7M
Volume
Months
6-9
2
2.4M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
2.5K
USD
1
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
FULC News & Events
Events Timeline
2025-07-29 (ET)
2025-07-29
06:57:44
Fulcrum Therapeutics' pociredir shows efficacy in sickle cell disease
2025-07-29
06:53:12
Fulcrum Therapeutics reports Q2 EPS (28c), consensus (29c)
2025-05-01 (ET)
2025-05-01
07:02:38
Fulcrum Therapeutics sees cash runway into at least 2027
Sign Up For More Events
Sign Up For More Events
News
5.0
08-08NewsfilterFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4.0
07-30BenzingaRBC Capital Maintains Sector Perform on Fulcrum Therapeutics, Raises Price Target to $5
9.5
07-30BenzingaAvis Budget Group Posts Downbeat Earnings, Joins SoFi Technologies, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Sign Up For More News
People Also Watch
MRT
Marti Technologies Inc
2.540
USD
+2.83%
LCNB
LCNB Corp
15.650
USD
+1.82%
AOUT
American Outdoor Brands Inc
9.750
USD
+6.44%
EVC
Entravision Communications Corp
2.640
USD
0.00%
FDMT
4D Molecular Therapeutics Inc
6.670
USD
+8.46%
FUNC
First United Corp
35.210
USD
+1.06%
ACB
Aurora Cannabis Inc
5.530
USD
+4.93%
LFMD
LifeMD Inc
6.890
USD
+0.88%
KVAC
Keen Vision Acquisition Corp
11.450
USD
0.00%
LRMR
Larimar Therapeutics Inc
3.720
USD
+0.54%
FAQ
What is Fulcrum Therapeutics Inc (FULC) stock price today?
The current price of FULC is 6.85 USD — it has increased 4.74 % in the last trading day.
What is Fulcrum Therapeutics Inc (FULC)'s business?
What is the price predicton of FULC Stock?
What is Fulcrum Therapeutics Inc (FULC)'s revenue for the last quarter?
What is Fulcrum Therapeutics Inc (FULC)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Fulcrum Therapeutics Inc (FULC)'s fundamentals?
How many employees does Fulcrum Therapeutics Inc (FULC). have?